Leber congenital amaurosis is an IRD caused by a defect in the CEP20 gene, resulting in progressive vision loss in infants. According to ClinicalTrials.gov, two new agents that target the CEP20 gene are currently in clinical trials:
The BRILLIANCE phase 1/2 clinical trial is investigating gene-editing techniques using CRISPR-Cas9 to delete the mutation in the CEP290 gene that is responsible for destroying light-sensing cells in the retina.
Phase 2/3 clinical trials are testing the antisense oligonucleotide sepofarsen. Significant improvement in vision has been reported in a case report 15 months after sepofarsen injection.
Other novel agents for Leber congenital amaurosis are in clinical trials.
Learn more about inherited retinal diseases.
Editor's Recommendations
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Donny W. Suh, Raj K. Maturi. Fast Five Quiz: Management of Inherited Retinal Diseases - Medscape - Mar 31, 2023.
Comments